What is the practical utility of serum interleukin‑6 (IL‑6) levels in diagnosing and managing neonatal sepsis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 28, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

IL-6 as a Rapid, Early Diagnostic Tool for Neonatal Sepsis

Serum IL-6 should be used as an early diagnostic biomarker for neonatal sepsis, measured at admission before antibiotics, with age-specific cutoffs: 80 pg/mL on day of life 1,40 pg/mL on days 2-7, and 30 pg/mL after day 7. This approach achieves 75% sensitivity and 81% specificity for culture-confirmed sepsis 1, and when combined with procalcitonin (PCT) and serum amyloid A (SAA), diagnostic accuracy increases dramatically to 93.3% sensitivity and 92.5% specificity 2.

Why IL-6 Matters: Timing is Everything

IL-6 rises before C-reactive protein (CRP) during infection, making it the superior early marker when rapid decision-making is critical for neonatal survival 3, 4. In late-onset sepsis, both IL-6 and adrenomedullin are elevated at admission, while CRP only becomes diagnostically useful by day 3 4. This temporal advantage is crucial—neonatal sepsis accounts for 22% of global neonatal deaths 5, and early appropriate antibiotics directly impact mortality.

Practical Implementation Algorithm

Step 1: Measure IL-6 at Admission (Before Antibiotics)

  • Day of life 1: Use cutoff >80 pg/mL
  • Days 2-7: Use cutoff >40 pg/mL
  • After day 7: Use cutoff >30 pg/mL
  • These cutoffs maintain 75% sensitivity and 81% specificity across all neonatal populations, including very preterm and very low birthweight infants 1

Step 2: Combine with Other Biomarkers for Maximum Accuracy

The triple panel (IL-6 + PCT + SAA) achieves an area under the curve (AUC) of 0.985, substantially outperforming any single marker 2:

  • IL-6 optimal cutoff: >52.8 pg/mL (AUC 0.908)
  • PCT optimal cutoff: >2.15 ng/mL (AUC 0.932)
  • SAA optimal cutoff: >28.6 mg/L (AUC 0.913)

Step 3: Use IL-6 for Severity Stratification and Prognosis

IL-6 is the only biomarker that reliably predicts mortality at all time points (AUC >0.90) 4. Significantly elevated IL-6 levels distinguish severe from mild/moderate sepsis (p<0.01) and correlate positively with severity scores 2. This helps guide intensity of treatment and need for escalation.

Step 4: Serial Monitoring Shows Favorable Kinetics

IL-6 demonstrates significantly greater negative rates of change over time compared to other biomarkers 6, making it useful for monitoring treatment response and supporting decisions about antibiotic de-escalation—consistent with Surviving Sepsis Campaign recommendations for daily antimicrobial assessment 7.

Critical Nuances and Caveats

Maternal factors can confound results: Intrapartum maternal fever (adjusted OR 18.1) is strongly associated with early-onset sepsis 8. Vaginal labor dynamics can elevate both IL-6 and CRP in healthy newborns, so interpret elevations in the context of maternal risk factors 8. The optimal IL-6 cutoff for early-onset sepsis may be higher (181 pg/mL) to account for labor-related stress 3.

Culture-negative vs culture-positive cases: IL-6 sensitivity is 90% in culture-positive sepsis but drops to 71.4% in culture-negative cases 3. This mirrors the Surviving Sepsis Campaign's weak recommendation for using procalcitonin to support discontinuation of empiric antibiotics when clinical evidence of infection is limited 7—IL-6 can serve a similar role.

Neonatal-specific performance: In broad neonatal populations, IL-6 sensitivity for sepsis is 67.6%, but increases to 81.2% when restricted to culture-positive or shock cases 6. This is still superior to CRP and neutrophil-lymphocyte ratio in neonates.

Integration with Current Sepsis Management

The provided guidelines focus on antimicrobial resistance patterns in low- and middle-income countries [5-5] and general sepsis management 7, 9, 10, but do not address biomarker-guided diagnosis. IL-6 fills this critical gap by enabling earlier identification before blood culture results (which take 24-72 hours) and before CRP rises.

Given that inappropriate empirical antibiotics increase mortality 5 and that WHO-recommended first-line antibiotics show high resistance rates in many settings 5, rapid IL-6-based diagnosis allows clinicians to:

  1. Confidently initiate appropriate empirical antibiotics early
  2. Avoid unnecessary antibiotics in non-infected neonates (reducing antimicrobial resistance)
  3. Escalate therapy promptly in severe cases based on IL-6 severity correlation

The Bottom Line for Clinical Practice

Use IL-6 as your first-line diagnostic biomarker for suspected neonatal sepsis, measured immediately at admission with age-specific cutoffs. Combine it with PCT and SAA when available for near-definitive diagnosis (>93% sensitivity and specificity). Use IL-6 levels to stratify severity and predict mortality risk. Serial IL-6 measurements guide treatment response better than CRP alone. This approach is minimally invasive, rapid (results within hours), and substantially improves diagnostic accuracy compared to traditional markers—directly impacting the morbidity and mortality outcomes that matter most.

References

Related Questions

At what dose of trazodone do adverse effects begin to be reported?
Is a 1000 mg dose of trazodone a dose that requires medical observation?
When can the mother of a 2‑year‑old child whose scalp laceration was closed with tissue adhesive in the emergency department safely wash the child's hair?
What is the next dose of vilazodone (40 mg orally daily) if dose escalation is needed?
Is there a diagram illustrating the hippocampal memory circuit (trisynaptic pathway)?
In a 20‑year‑old male chronic alcoholic presenting with icterus, elevated total bilirubin, elevated direct and indirect bilirubin, markedly elevated aspartate aminotransferase (AST) and alanine aminotransferase (ALT), normal total protein, albumin, hemoglobin, white blood cell count and platelet count, neutrophil percentage 45.8% and lymphocyte percentage 41.8%, what is the diagnosis and the appropriate treatment with dosages?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.